Stereotactic radiotherapy and cytokines: preliminary analysis in oligometastatic Non-Small-Cell lung cancer

被引:1
作者
Borghetti, P. [1 ]
Guerini, A. E. [1 ]
Colosini, A. [2 ]
Facheris, G. [1 ]
Gandolfo, C. [3 ]
Triggiani, L. [1 ]
Bruni, A. [4 ]
D'Angelo, E. [4 ]
Cusi, M. Grazia [3 ]
Magrini, S. M. [1 ]
Bresciani, R. [2 ]
Nardone, V. [5 ]
机构
[1] Univ & Spedali Civili Hosp Brescia, Dept Radiat Oncol, Ple Spedali Civili 1, I-25123 Brescia, Italy
[2] Univ Brescia, Dept Mol & Translat Med, Unit Biotechnol, Brescia, Italy
[3] Univ Siena, Le Scotte Hosp, Dept Med Biotechnol, Microbiol Unit, Siena, Italy
[4] Univ Hosp Modena, Dept Hematol & Oncol, Radiotherapy Unit, Modena, Italy
[5] Univ Campania L Vanvitelli, Dept Precis Oncol, Naples, Italy
来源
INTERNATIONAL JOURNAL OF RADIATION RESEARCH | 2023年 / 21卷 / 02期
关键词
Stereotactic radiotherapy; cytokines; oligometastatic; lung cancer; ABLATIVE RADIOTHERAPY; RADIATION; IMMUNOTHERAPY; PNEUMONITIS; RECEPTOR;
D O I
10.52547/ijrr.21.2.10
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Background: Cytokines have a recognized role in the physiopathology of cancer disease and could be involved also in the "abscopal effect". Aim of this work is the preliminary analysis of inflammatory mediators in patients with oligometastatic non-small-cell lung cancer (NSCLC) undergoing stereotactic radiotherapy (SRT). Materials and Methods: This was a feasibility multi-institutional study that prospectively included oligometastatic NSCLC patients undergoing SRT from June 2018 until August 2018 and healthy controls. Blood samples were collected at three different time points (1-5 days before SRT, 1-5 days after SRT and 28-35 days after SRT). A commercially available kit was used for quantitative analysis of 44 inflammation molecules. Nine patients and four healthy controls were enrolled. Results: Several cytokines (54.5%) resulted undetectable in a significant percentage of the samples and were not further analyzed. Levels of seven inflammatory molecules (bDNF, MIP-1b, PDGF-bb, PIGF-1, RANTES, SDF1-a, and bNGF) showed significant variations after SRT in the NSCLC patients cohort. Conclusion: Significant plasmatic concentration changes after SRT were reported for a relevant proportion of the evaluated molecules. The results of this study will contribute to define a selection of cytokines and chemokines that will be analyzed in a prospective trial with a larger sample of patients.
引用
收藏
页码:247 / 254
页数:8
相关论文
共 48 条
[1]   Multifaceted Role of the Placental Growth Factor (PlGF) in the Antitumor Immune Response and Cancer Progression [J].
Albonici, Loredana ;
Giganti, Maria Gabriella ;
Modesti, Andrea ;
Manzari, Vittorio ;
Bei, Roberto .
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2019, 20 (12)
[2]   The Inflammatory Chemokine CCL5 and Cancer Progression [J].
Aldinucci, Donatella ;
Colombatti, Alfonso .
MEDIATORS OF INFLAMMATION, 2014, 2014
[3]   Nerve growth factor: role in growth, differentiation and controlling cancer cell development [J].
Aloe, Luigi ;
Rocco, Maria Luisa ;
Balzamino, Bijorn Omar ;
Micera, Alessandra .
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2016, 35
[4]  
[Anonymous], 2015, J CLIN ONCOL
[5]   Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy [J].
Apetoh, Lionel ;
Ghiringhelli, Francois ;
Tesniere, Antoine ;
Obeid, Michel ;
Ortiz, Carla ;
Criollo, Alfredo ;
Mignot, Gregoire ;
Maiuri, M. Chiara ;
Ullrich, Evelyn ;
Saulnier, Patrick ;
Yang, Huan ;
Amigorena, Sebastian ;
Ryffel, Bernard ;
Barrat, Franck J. ;
Saftig, Paul ;
Levi, Francis ;
Lidereau, Rosette ;
Nogues, Catherine ;
Mira, Jean-Paul ;
Chompret, Agnes ;
Joulin, Virginie ;
Clavel-Chapelon, Francoise ;
Bourhis, Jean ;
Andre, Fabrice ;
Delaloge, Suzette ;
Tursz, Thomas ;
Kroemer, Guido ;
Zitvogel, Laurence .
NATURE MEDICINE, 2007, 13 (09) :1050-1059
[6]   Essential role of immobilized chemokine CXCL12 in the regulation of the humoral immune response [J].
Barinov, Aleksandr ;
Luo, Lingjie ;
Gasse, Pamela ;
Meas-Yedid, Vannary ;
Donnadieu, Emmanuel ;
Arenzana-Seisdedos, Fernando ;
Vieira, Paulo .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2017, 114 (09) :2319-2324
[7]   Immunotherapy and stereotactic ablative radiotherapy (ISABR): a curative approach? [J].
Bernstein, Michael B. ;
Krishnan, Sunil ;
Hodge, James W. ;
Chang, Joe Y. .
NATURE REVIEWS CLINICAL ONCOLOGY, 2016, 13 (08) :516-524
[8]   Combining immunotherapy and radiotherapy in lung cancer [J].
Bhalla, Neeraj ;
Brooker, Rachel ;
Brada, Michael .
JOURNAL OF THORACIC DISEASE, 2018, 10 :S1447-S1460
[9]   Concomitant radiotherapy and TKI in metastatic EGFR- or ALK-mutated non-small cell lung cancer: a multicentric analysis on behalf of AIRO lung cancer study group [J].
Borghetti, Paolo ;
Bonu, Marco Lorenzo ;
Giubbolini, Rachele ;
Levra, Niccolo' Giaj ;
Mazzola, Rosario ;
Perna, Marco ;
Visani, Luca ;
Meacci, Fiammetta ;
Taraborrelli, Maria ;
Triggiani, Luca ;
Franceschini, Davide ;
Greco, Carlo ;
Bruni, Alessio ;
Magrini, Stefano Maria ;
Scotti, Vieri .
RADIOLOGIA MEDICA, 2019, 124 (07) :662-670
[10]   Radiotherapy and Tyrosine Kinase Inhibitors in Stage IV Non-small Cell Lung Cancer: Real-life Experience [J].
Borghetti, Paolo ;
Bonu, Marco Lorenzo ;
Roca, Elisa ;
Pedretti, Sara ;
Salah, Emiliano ;
Baiguini, Anna ;
Greco, Diana ;
Triggiani, Luca ;
Maddalo, Marta ;
Levra, Niccolo Giaj ;
Alongi, Filippo ;
Magrini, Stefano Maria ;
Buglione, Michela .
IN VIVO, 2018, 32 (01) :159-164